Can selective serotonin reuptake inhibitors (SSRIs) cause epistaxis?

SSRIs Can Cause Nosebleeds

Yes, SSRIs can cause epistaxis (nosebleeds), though this is an uncommon adverse effect that occurs through impairment of platelet function. The mechanism involves depletion of platelet serotonin stores, which are necessary for normal platelet aggregation and hemostasis 1, 2.

Mechanism and Evidence

SSRIs inhibit serotonin reuptake not only in the central nervous system but also in platelets, where serotonin plays a critical role in clot formation. This leads to:

• Decreased platelet aggregation
• Prolonged bleeding time in some patients
• Increased capillary fragility 1

The bleeding risk is dose-dependent, with escitalopram showing particularly strong associations at higher doses 3. Among SSRIs, pharmacovigilance data shows varying rates of bleeding events: escitalopram (2.85%), citalopram (1.93%), paroxetine (1.29%), sertraline (1.25%), fluvoxamine (1.05%), and fluoxetine (1.02%) 4.

Clinical Presentation

Epistaxis typically develops 1 week to 3 months after starting SSRI treatment 5. The bleeding is usually:

• Self-limited
• Resolves within 2 days to 4 months after discontinuation 1
• More common in patients over 65 years old 4
• More frequent in females 4

Critical Risk Factors

The risk of epistaxis increases substantially when SSRIs are combined with:

• Antiplatelet agents (most common concomitant medication, 4.4% of cases) 4
• NSAIDs (2.6% of cases) 4
• Direct oral anticoagulants (DOACs) (2.3% of cases) 4
• Warfarin (0.4% of cases) 4
• Vitamin K antagonists (OR 3.55) 6
• Heparin preparations 6

Additional medical conditions that amplify risk include hypertension, chronic sinusitis, and other nasal disorders 6.

Management Algorithm

When epistaxis occurs on an SSRI:

1. First-line approach: Dose reduction may be sufficient without complete discontinuation 3
2. Acute bleeding management follows standard epistaxis protocols 7:
   • Topical vasoconstrictors (oxymetazoline, phenylephrine)
   • Nasal cautery if bleeding site identified
   • Moisturizing agents after bleeding stops
3. Review all concomitant medications for additive bleeding risk 4
4. Consider switching to antidepressants with lower bleeding risk (tricyclics or atypical antidepressants) if epistaxis is recurrent or severe 2

Important Caveats

• Do not assume normal routine hematologic labs exclude SSRI-related bleeding—bleeding time or platelet function may be abnormal even with normal platelet counts 5
• The 2020 epistaxis guidelines 7 do not specifically address SSRI-related bleeding, focusing instead on local nasal factors and hereditary conditions like HHT
• Gastroprotective agents should be considered when SSRIs are combined with anticoagulants or antiplatelet drugs, though this primarily addresses GI bleeding risk 2

Clinical Decision Point

For patients requiring both SSRI therapy and anticoagulation/antiplatelet therapy: Conduct individualized bleeding risk assessment weighing psychiatric benefit against hemorrhagic risk. The cumulative risk with multiple agents is substantial 8. Consider alternative antidepressants with lower bleeding profiles (bupropion, mirtazapine) when feasible 2.